{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:20:02Z","timestamp":1789042802444,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017619","name":"Northwest Minzu University","doi-asserted-by":"publisher","award":["31920240080"],"award-info":[{"award-number":["31920240080"]}],"id":[{"id":"10.13039\/501100017619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA003"],"award-info":[{"award-number":["23ZDFA003"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["lzujbky-2022-sp09"],"award-info":[{"award-number":["lzujbky-2022-sp09"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmc.2025.118473","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:49:53Z","timestamp":1761810593000},"page":"118473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms"],"prefix":"10.1016","volume":"132","author":[{"given":"Xi-Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Jing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118473_bb0005","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1021\/cr5002904","article-title":"Chemical methods for decoding cytosine modifications in DNA","volume":"115","author":"Booth","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2025.118473_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm3785","article-title":"The dynamic epitranscriptome: N6-methyladenosine and gene expression control","volume":"15","author":"Meyer","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2025.118473_bb0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acschembio.5b00864","article-title":"Reading the combinatorial histone language","volume":"11","author":"Su","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2025.118473_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102352","article-title":"Uncovering post-translational modification-associated protein-protein interactions","volume":"74","author":"Wang","year":"2022","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmc.2025.118473_bb0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.06.013","article-title":"Post-translational modifications of transporters","volume":"192","author":"Czuba","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118473_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tig.2018.11.002","article-title":"Post-translational modification, phase separation, and robust gene transcription","volume":"35","author":"Singh","year":"2019","journal-title":"Trends Genet"},{"key":"10.1016\/j.bmc.2025.118473_bb0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/1568026615666150302110135","article-title":"Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential","volume":"15","author":"Yu","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143606","article-title":"Functional roles of Bromodomain proteins in Cancer","volume":"13","author":"Boyson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2025.118473_bb0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.jmedchem.5b01514","article-title":"Disrupting acetyl-lysine recognition: Progress in the development of Bromodomain inhibitors","volume":"59","author":"Romero","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0050","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting Bromodomain and Extraterminal proteins for drug discovery: from current Progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0055","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/nn.4095","article-title":"BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice","volume":"18","author":"Korb","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmc.2025.118473_bb0060","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","article-title":"Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release","volume":"155","author":"Liu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118473_bb0070","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.molcel.2016.12.022","article-title":"Distinct roles of Brd2 and Brd4 in potentiating the transcriptional program for Th17 cell differentiation","volume":"65","author":"Cheung","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrm3953","article-title":"Getting up to speed with transcription elongation by RNA polymerase II","volume":"16","author":"Jonkers","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2025.118473_bb0080","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0085","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET Bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2025.118473_bb0090","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate Cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2025.118473_bb0095","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1093\/nar\/gkx561","article-title":"BRD4 inhibitors block telomere elongation","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2025.118473_bb0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","article-title":"Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer","volume":"25","author":"Shi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0105","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-13-0122-T","article-title":"BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy","volume":"73","author":"Segura","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118473_bb0110","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/ijc.29568","article-title":"Histo-genomic stratification reveals the frequent amplification\/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma","volume":"137","author":"Goundiam","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2025.118473_bb0115","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.4049\/jimmunol.1202838","article-title":"BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses","volume":"190","author":"Belkina","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2025.118473_bb0120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/15592294.2015.1034416","article-title":"Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma","volume":"10","author":"Sengupta","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.bmc.2025.118473_bb0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2025.118473_bb0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118473_bb0140","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1021\/acs.jmedchem.4c03069","article-title":"Multi-water bridges enable design of BET BD1-selective inhibitors for pancreatic Cancer therapy","volume":"68","author":"Chen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0145","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1615601114","article-title":"BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice","volume":"114","author":"Cheung","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118473_bb0150","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1021\/jm401334s","article-title":"Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains","volume":"56","author":"Zhang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0155","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable Chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0160","article-title":"Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor","volume":"109","author":"Hagihara","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118473_bb0165","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1021\/acs.jmedchem.4c02128","article-title":"Design of Selective BRD4 inhibitors for the treatment of autosomal dominant polycystic kidney disease","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molmed.2019.06.009","article-title":"The mitochondrion as an emerging therapeutic target in Cancer","volume":"26","author":"Roth","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bmc.2025.118473_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107325","article-title":"Dual inhibition of oxidative phosphorylation and glycolysis to enhance cancer therapy","volume":"147","author":"Sheng","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0180","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/acsptsci.5c00068","article-title":"Orally bioavailable BRD4 BD1 inhibitor ZL0516 effectively suppresses colonic inflammation in animal models of inflammatory bowel disease","volume":"8","author":"Ma","year":"2025","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.bmc.2025.118473_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117272","article-title":"Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4","volume":"285","author":"Liu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117822","article-title":"Development of a potent BET inhibitor for the treatment of renal fibrosis","volume":"295","author":"Huang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-17-0902","article-title":"BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor","volume":"8","author":"Ozer","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118473_bb0200","article-title":"Lysine-targeting, covalent inhibitors of Bromodomain BD1 of BET proteins in live cells and animals","volume":"64","author":"Li","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmc.2025.118473_bb0205","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.jmedchem.2c00100","article-title":"Structure-based discovery and optimization of Furo[3,2-c]pyridin-4(5H)-one derivatives as potent and second Bromodomain (BD2)-selective Bromo and extra terminal domain (BET) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0210","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the first BRD4 second Bromodomain (BD2)-selective inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117193","article-title":"Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity","volume":"284","author":"Chen","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0220","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1021\/acs.jmedchem.5b00099","article-title":"Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast Cancer","volume":"58","author":"Tang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","article-title":"An update on dual targeting strategy for cancer treatment","volume":"349","author":"Taghipour","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2025.118473_bb0230","doi-asserted-by":"crossref","first-page":"696","DOI":"10.18632\/oncotarget.2673","article-title":"Cyclin E1 and RTK\/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS","volume":"6","author":"Taylor-Harding","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118473_bb0235","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1038\/srep15365","article-title":"Interaction of Cx43 with Hsc70 regulates G1\/S transition through CDK inhibitor p27","volume":"5","author":"Hino","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118473_bb0240","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118473_bb0245","doi-asserted-by":"crossref","first-page":"21186","DOI":"10.1021\/acs.jmedchem.4c01976","article-title":"Discovery of dual CDK6\/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of Ferroptosis in triple-negative breast Cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117495","article-title":"Discovery of dual CDK4\/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo","volume":"290","author":"Zhang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0255","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1021\/acs.jmedchem.4c02478","article-title":"Design, synthesis, and biological evaluation of Thieno[3,2-d]pyrimidine derivatives as the first bifunctional PI3K\u03b4 isoform selective\/Bromodomain and extra-terminal inhibitors","volume":"68","author":"Ran","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0260","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2025.118473_bb0265","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3389\/fimmu.2019.02056","article-title":"STAT3 mediates the differential effects of Oncostatin M and TNF\u03b1 on RA synovial fibroblast and endothelial cell function","volume":"10","author":"Hanlon","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2025.118473_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102317","article-title":"Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer","volume":"52","author":"Ouyang","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.bmc.2025.118473_bb0275","doi-asserted-by":"crossref","first-page":"1560559","DOI":"10.3389\/fphar.2025.1560559","article-title":"A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118473_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116663","article-title":"Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia","volume":"276","author":"Liu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0285","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118473_bb0290","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1021\/acs.jmedchem.3c00614","article-title":"Selective HDAC3 inhibitors with potent in vivo antitumor efficacy against triple-negative breast Cancer","volume":"66","author":"Pulya","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0295","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1021\/acs.jmedchem.0c01676","article-title":"Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy","volume":"64","author":"Adhikari","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117230","article-title":"Discovery of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids as HDAC3\/BRD4 dual inhibitors and anti-tumor agents","volume":"285","author":"Li","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010187","article-title":"Multiple roles of PLK1 in mitosis and meiosis","volume":"12","author":"Kalous","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118473_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113314","article-title":"Recent progress in agents targeting polo-like kinases: promising therapeutic strategies","volume":"217","author":"Zhang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117886","article-title":"Achieving dual-target fluorescent probes for tracing and inhibiting BRD4\/PLK1 in tumor cells and tissues synchronously","volume":"296","author":"Gao","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0320","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.bmc.2025.118473_bb0325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","article-title":"RING domain E3 ubiquitin ligases","volume":"78","author":"Deshaies","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2025.118473_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202401051","article-title":"Integrating proteolysis-targeting chimeras (PROTACs) with delivery Systems for More Efficient and Precise Targeted Protein Degradation","volume":"46","author":"Lin","year":"2025","journal-title":"Macromol Rapid Commun"},{"key":"10.1016\/j.bmc.2025.118473_bb0335","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","article-title":"Emerging roles of and therapeutic strategies targeting BRD4 in cancer","volume":"337","author":"White","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bmc.2025.118473_bb0340","doi-asserted-by":"crossref","first-page":"19428","DOI":"10.1021\/acs.jmedchem.4c01767","article-title":"Design, synthesis, and activity evaluation of BRD4 PROTAC based on alkenyl Oxindole-DCAF11 pair","volume":"67","author":"Zhao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117159","article-title":"Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines","volume":"241","author":"Hu","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118473_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500133","article-title":"Hijacking the MDM2 E3 ligase with novel BRD4-targeting proteolysis-targeting chimeras in pancreatic Cancer cells","volume":"26","author":"Ficu","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2025.118473_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911068","article-title":"MDM2-based proteolysis-targeting chimeras (PROTACs): An innovative drug strategy for Cancer treatment","volume":"23","author":"Vicente","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118473_bb0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118473_bb0365","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2024.08.044","article-title":"Liver-targeting chimeras as a potential modality for the treatment of liver diseases","volume":"374","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2025.118473_bb0370","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.7150\/thno.113852","article-title":"Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2025.118473_bb0375","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1021\/acs.jmedchem.5c00468","article-title":"GLUTs-facilitated targeting BRD4 degradation in breast Cancer through carbohydrate-conjugated PROTACs","volume":"68","author":"Gao","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0380","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118473_bb0385","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118473_bb0390","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118473_bb0395","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118473_bb0400","article-title":"Smart Nano-PROTACs reprogram tumor microenvironment for Activatable photo-metabolic Cancer immunotherapy","volume":"61","author":"Zhang","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmc.2025.118473_bb0405","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/jacs.3c04109","article-title":"Self-assembled Nano-PROTAC enables near-infrared photodynamic proteolysis for Cancer therapy","volume":"145","author":"Wang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118473_bb0410","article-title":"Nano proteolysis targeting chimeras (PROTACs) with anti-hook effect for tumor therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmc.2025.118473_bb0415","article-title":"Versatile Nano-PROTAC-induced epigenetic reader degradation for efficient lung Cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bmc.2025.118473_bb0420","first-page":"414","article-title":"pH\/GSH dual responsive nanosystem for nitric oxide generation enhanced type I photodynamic therapy","volume":"34","author":"Zou","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.bmc.2025.118473_bb0425","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1074\/jbc.RA117.000443","article-title":"Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1","volume":"293","author":"Fahey","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118473_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123387","article-title":"Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy","volume":"322","author":"Li","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmc.2025.118473_bb0435","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-019-1847-2","article-title":"Metabolic heterogeneity confers differences in melanoma metastatic potential","volume":"577","author":"Tasdogan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118473_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122463","article-title":"Nano-enhanced immunotherapy: targeting the immunosuppressive tumor microenvironment","volume":"305","author":"Jin","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmc.2025.118473_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab012","article-title":"Response rate and survival at key Timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: Meta-analysis of metastatic NSCLC trials","volume":"5","author":"Man","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.bmc.2025.118473_bb0450","doi-asserted-by":"crossref","first-page":"11855","DOI":"10.1021\/acsnano.3c03166","article-title":"Microneedle patch delivery of PROTACs for anti-Cancer therapy","volume":"17","author":"Cheng","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bmc.2025.118473_bb0455","doi-asserted-by":"crossref","first-page":"25830","DOI":"10.1021\/acsnano.5c04580","article-title":"Oxygen-generating transdermal Nanoplatform Codelivering BRD4 proteolysis-targeting chimera\/Verteporfin\/CaO(2) synergistically remodels immunosuppressive melanoma microenvironment to potentiate combination immunotherapy","volume":"19","author":"Wei","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bmc.2025.118473_bb0460","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1038\/s41467-022-31799-y","article-title":"Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118473_bb0465","article-title":"Biomimetic hybrid PROTAC Nanovesicles block multiple DNA repair pathways to overcome Temozolomide resistance against Orthotopic glioblastoma","volume":"37","author":"Xu","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.bmc.2025.118473_bb0470","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118473_bb0475","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1038\/s41467-022-34024-y","article-title":"Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer","volume":"13","author":"Ding","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118473_bb0480","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","article-title":"Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal Cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118473_bb0485","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118473_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102212","article-title":"BET inhibitor and CDK4\/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair","volume":"51","author":"Chi","year":"2025","journal-title":"Transl Oncol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:05:35Z","timestamp":1780635935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":98,"alternative-id":["S0968089625004146"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118473","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118473"}}